替硝唑葡萄糖注射液的稳定性研究

采用反相ＨＰＬＣ法测定替硝唑葡萄糖注射液中替硝唑的含量，用加温加速实验研究该制剂的热稳定动力学。结果表明，替硝唑的热降解反应为一级动力学过程，在５０、６５、８０、９５℃时的降解速度常数分别为５．５８×１０－４、２．６６×１０－３、８．１０×１０－３、２．８２×１０－２ｄ－１，为８．３年，半衰期为３９．５年。     

体外静脉—静脉转流下原位肝移植围术期酸碱,生化的变化

目的:观察体外静脉转流下原位肝移植围术期酸碱和生化的变化。方法:7例病人行原位肝移植术,在无肝期行体外静脉-静脉转流,监测围术期酸碱和生化指标。结果:(1)与术前相比,pH各期有所下降,但仍维持在正常范围,BE和SBC在转流60分钟及关腹时降低;与转流前期相比。pH以后各期变化不大。术期pH在7.35～7.45范围之内;(2)血糖在各期都升高,血钙降低,体温逐渐降低;(3)血钾在肝血管开放后一过性增高,由3.17mmol/L升至3.53mmol/L。结论;体外静脉转流下原位肝移植术,术中酸碱和生化变化轻微,避免了明显的代谢性酸中毒和高血钾,但体温和血糖变化明显。     

上腹器官簇移植术实验中血流动力学及血生化的变化

目的:观察上腹器官簇移植术实验中血流动力学及血生化变化。方法:杂种猪32只。随机分为供体组和受体组,无肝期行体外静脉转流。测定术中的血流动力学和血生化指标。结果:(1)术中血流动力学在无肝期初期及开放后早期时间内有明显的波动,心输出量、血压、肺动脉压和肺毛细血管楔压下降,心率加快;(2)转流在一定程度上稳定血流动力学;(3)生化变化:开放前行肝冲洗的8例,血钾仅轻度升高;未作冲洗的6例,则血钾明显升高;(4)开放后均有不同程度的代谢性酸中毒。结论:上腹器官簇移植术,机体血流动力学及血生化均有改变,特别是在肝移植阶段明显。其它器官移植期处理也应考虑肝移植后续作用的影响。     

猪门静脉回流阻断模型内毒素的移位

【目的】拟在猪的肠血管阻断模型中探讨门静脉回流阻断肠淤血可能造成的内毒素移位和肿瘤坏死因子释放。【方法】采用种群相近体质量22～25kg雌性小猪8只，无感染症状。分离门静脉和肝后下腔静脉分别阻断、然后开放各60min．观察血压、心率，阻断前和开放60min各取回肠末端小肠全层行光镜、电镜检查，测定门、颈静脉血内毒素及肿瘤坏死因子（TNF—α）含量。【结果】门静脉和肝后下腔静脉阻断后，肠淤血、水肿，并随时间延长而加重，光镜检查表明实验后肠粘膜和腺体明显损伤，电镜检查表明细胞超微结构轻微异常。阻断前后的血内毒素、TNF—α含量无显著性差异。【结论】①肠静脉回流阻断60min引起的肠道淤血可导致肠粘膜屏障损伤。②在60min内肠淤血性的损伤不会引起肠腔内内毒素的大量移位及TNF—α的释放。     

葛根素对异丙肾上腺素诱导大鼠心肌损伤的保护作用

采用异丙肾上腺素造成大鼠急性心肌缺血模型 ,观察葛根素对大鼠心电图、血清磷酸肌酸激酶 (CPK)、心肌组织超氧化物歧化酶 (SOD)和脂质过氧化物丙二醛 (MDA)的影响。发现葛根素可对抗异丙肾上腺素所致心肌缺血大鼠的心电图ST段的异常升高 ,使血清CPK降低 ,并可增加心肌组织SOD的活力 ,减少MDA生成。提示 :葛根素对大鼠心肌缺血有保护作用     

Dll4-Notch信号传递途径在血管发生中的作用

血管发生(angiogenesis)依赖多种促进血管发生因子和抑制血管发生因子之综合的交互作用所调控。血管内皮生长因子(VEGF)和Notch信号传递途径(Notch signaling pathway)参与此过程。之前研究已证明Notch信号传递途径在胚胎发育和肿瘤血管发生(tumour angiogenesis)中扮演重要的角色,而最近研究则发现在血管发育过程中Dll4-Notch信号传递途径扮演着前所未知的新角色,并阐明因Notch信号传递减少而引起血管缺陷之机制,从而揭示破坏肿瘤血管发生的新药物靶点。本文着重于介绍Notch信号传递途径的组成;Dll4-Notch在血管发生中的作用;以及Dll4-Notch对肿瘤治疗的意义。     

银杏叶注射液对实验性大鼠局灶性脑缺血的保护作用

以行为障碍、脑梗死范围、脑含水量、脑组织病理改变为观察指标,研究银杏叶注射液（ＧＢＥ）对大鼠大脑中动脉闭塞所致局部脑缺血的防治作用。结果表明,ＧＢＥ２０、４０ｍｇ／ｋｇ静脉注射可显著降低大鼠脑梗死范围和脑含水量,改善行为障碍。脑组织形态学检查显示,ＧＢＥ４０ｍｇ／ｋｇ组动物脑组织缺血病变较轻。提示ＧＢＥ对局灶性脑缺血具有保护作用。     

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

Over the past decade, treatment options for patients with multiple myeloma (MM) have improved substantially, resulting in better response rates and prolonged overall survival (OS). Nevertheless, MM remains a challenging disease, especially if renal insufficiency (RI) or extensive pre-treatment aggravates the assignment of the optimal treatment schedule. In this retrospective study, we analyzed the outcome of lenalidomide plus dexamethasone in 167 patients with relapsed or refractory MM with focus on RI. The baseline creatinine clearance (CL_Cr) was normal in 94 patients (CL_Cr ≥ 80 ml/min), while RI was observed in 73 patients, including 40 patients with mild RI (50 ≤ CL_Cr < 80 ml/min) and 33 patients with moderate or severe RI (CL_Cr < 50 ml/min). Response rates declined depending on the severity of RI, being 67% among patients with normal kidney function, 60% among patients with mild RI and 49% among patients with moderate or severe RI. Time to progression (TTP) was significantly reduced in patients with severe RI and in case of >2 previous treatment lines. OS was not significantly different between patients with normal and impaired renal function. In contrast, the number of previous treatment lines (2 vs. <2) and the use of novel agents like bortezomib or thalidomide prior to lenalidomide plus dexamethasone therapy had a more adverse effect on OS. In conclusion, lenalidomide plus dexamethasone is an effective regimen for relapsed or refractory patients with MM complicated by RI with manageable toxicity.